Ginkgo Bioworks
27 Drydock Avenue
8th Floor
Boston
Massachusetts
02210
United States
Tel: 814-HACK-DNA
Website: http://ginkgobioworks.com/
265 articles about Ginkgo Bioworks
-
Modalis Announces Partnership with Ginkgo Bioworks
4/12/2024
Modalis Therapeutics Corporation announced that it has entered into an agreement with Ginkgo Bioworks to join the Ginkgo Technology Network.
-
Ginkgo Bioworks Previews Today's Annual Ferment Conference, Announces "Lab Data as a Service"
4/11/2024
Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, is hosting its 5th annual Ferment conference.
-
Ginkgo Bioworks Announces Acquisition of AgBiome's Platform Assets
4/11/2024
Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced the acquisition of AgBiome's platform assets, including over 115,000 fully sequenced and isolated strains, over 500 million unique gene sequences, and relevant functional data and metadata, as well as AgBiome's development pipeline.
-
Ginkgo Bioworks Awarded Grant for AI-enabled Forecasting of Measles Outbreaks
4/10/2024
Ginkgo Bioworks today announced that it has been awarded a grant from the Bill & Melinda Gates Foundation to build an open-access, AI-enabled measles forecasting model to empower proactive public health measures, such as immunization campaigns, in partnership with Northeastern University researchers Alessandro Vespignani and Sam Scarpino.
-
Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain
4/10/2024
Ginkgo Bioworks today announced the expansion of its strategic partnership with global healthcare leader Novo Nordisk under a framework agreement that initially is contemplated to run over five years.
-
IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service
4/8/2024
IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, announced that is has entered into an agreement with Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, to join the Ginkgo Technology Network.
-
Ginkgo Bioworks to Host 5th Annual Ferment Conference
4/4/2024
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its annual conference, Ferment, on Thursday, April 11, 2024 in Boston, MA.
-
Prozomix and Ginkgo Bioworks Collaborate on Next-Gen Enzyme Development for Sustainable API Manufacturing
4/3/2024
Prozomix, a UK-based biotech company focused on novel biocatalyst discovery and manufacturing, and Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced a new partnership.
-
Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Assets to Strengthen Next-Gen CAR Designs
4/2/2024
Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced the acquisition of Modulus Therapeutics' cell therapy platform assets, including their chimeric antigen receptor and switch receptor libraries.
-
Ginkgo Bioworks Awarded DARPA Funding to Produce Novel Proteins to Control Ice in Extreme Cold Weather Environments
3/28/2024
Ginkgo Bioworks announced that it has been awarded a contract for up to $6 million from the Defense Advanced Research Projects Agency to achieve DARPA's objectives under its new Ice Control for cold Environments program.
-
bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network
2/28/2024
bit.bio, the company coding human cells for novel cures, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced bit.bio as an inaugural partner of the Ginkgo Technology Network.
-
Ginkgo Technology Network Launches, Providing an Integrated R&D Experience with Capabilities from Over 25 Inaugural Partners
2/28/2024
Ginkgo Bioworks announced the creation of the Ginkgo Technology Network - a groundbreaking ecosystem of cutting edge technology partners, each committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer R&D programs.
-
Ginkgo Bioworks Acquires Reverie Labs Platform, Enhancing AI-Driven Drug Discovery Capabilities for Customer Programs
2/28/2024
Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of key assets of Reverie Labs, which built and used AI/ML tools to accelerate drug discovery. Ginkgo has acquired Reverie's infrastructure and software for training large-scale AI foundation models.
-
Ginkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its Customers
2/28/2024
Today, Ginkgo Bioworks announced the acquisition of Proof Diagnostics, an innovative life sciences tools, diagnostics and computational discovery company which uncovered genome engineering tools for both therapeutic and diagnostics applications.
-
Ginkgo Bioworks Acquires Patch Biosciences, Expanding Suite of Genetic Medicine Capabilities Available to Customers
2/28/2024
Today, Ginkgo Bioworks announced the acquisition of Patch Biosciences, which has built an AI platform for sequence design that enables more effective, specific, and durable genetic medicines.
-
Form Bio and Ginkgo Partner to Develop Industry-Leading Solutions for AAV Gene Therapy Design and Development
2/28/2024
Form Bio and Ginkgo Bioworks today announced a new partnership to provide a complete and holistic solution offering for AAV gene therapy design and development.
-
Ginkgo Biosecurity Launches Doha-Based Pathogen Monitoring Center, CUBE-D, Establishing Middle East Hub for Global Bioradar, at Qatar Free Zones
2/27/2024
Ginkgo Bioworks has announced the signing of an agreement with Qatar Free Zones Authority and Doha Venture Capital to build the first Center for Unified Biosecurity Excellence in Doha within Qatar Free Zones.
-
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2023 Results Presentation
2/22/2024
Ginkgo Bioworks today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, beginning at 5:30 p.m. ET.
-
Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design
2/15/2024
The Defense Threat Reduction Agency's Joint Science and Technology Office for the Chemical and Biological Defense Program has awarded, through the Medical CBRN [Chemical, Biological, Radiological, and Nuclear] Defense Consortium requirement 22-05, "Adjuvant Activity to Vaccines Prototype," a 5-year contract totaling up to $31 million including program options to the team of Ginkgo Bioworks, Inc.
-
House Select Committee Tours Ginkgo Bioworks, Previews Biofab1, Ginkgo's New Integrated Data Generation Facility Set to Launch in 2025
2/13/2024
Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, hosted members of Congress focused on strengthening the U.S. bioeconomy in service of national and economic security yesterday.